Regeneron

News

Genetic testing hopes to speed up drug development in rare eye diseases

Oxurion reports stronger data for diabetic eye disease drug

Belgian biotech Oxurion has revealed new data from a phase 2 trial of its plasma kallikrein inhibitor THR-149, in development for people with

News

Pfizer sees no way forward for Ionis-partnered vupanorsen

Pfizer has called time on its alliance with Ionis for cholesterol-lowering therapy vupanorsen, after a review of phase 2b data raised some questions about the antisense drug's efficacy and

News

Roche grabs FDA okay for would-be blockbuster eye drug faric...

The FDA has approved Roche's much-anticipated faricimab for two major causes of blindness, setting up a market clash with Bayer and Regeneron's market leading drug Eylea.

News

scientifically visualization of a coronavirus spike protein

FDA bans use of Lilly, Regeneron COVID drugs due to Omicron

The FDA has limited the use of COVID-19 antibody therapies developed by Eli Lilly and Regeneron, on the back of data suggesting they have are "highly unlikely" to be effective against the n

News

After FDA setback, Ipsen gets first OK for rare disease drug...

After regulatory hold-ups in the US and Europe, Ipsen has claimed a confidence-boosting approval in Canada for palovarotene, a rare disease therapy acquired via its $1.3 billion takeover of

News

Regeneron hands ex-US rights to HoFH drug Evkeeza to Ultrage...

Regeneron has enlisted the aid of Ultragenyx to add momentum to the rollout of its recently-approved Evkeeza outside the US, which was approved for an inherited form of elevated cholesterol

Oxurion reports stronger data for diabetic eye disease drug

Pfizer sees no way forward for Ionis-partnered vupanorsen

Roche grabs FDA okay for would-be blockbuster eye drug faric...

FDA bans use of Lilly, Regeneron COVID drugs due to Omicron

After FDA setback, Ipsen gets first OK for rare disease drug...

Regeneron hands ex-US rights to HoFH drug Evkeeza to Ultrage...

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Regeneron

Editor's Picks